On Friday, March 3, 2006, a trademark application was filed for GEOGENETICS with the United States Patent and Trademark Office. The USPTO has given the GEOGENETICS trademark a serial number of 78828819. The federal status of this trademark filing is ABANDONED – FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, May 21, 2009. This trademark is owned by GeoGenetics Inc.. The GEOGENETICS trademark is filed in the Natural Agricultural Products and Computer & Software Services & Scientific Services categories with the following description:
Plant products, namely, live transgenic plants, dried transgenic plants, and transgenic plant seeds
Scientific research for others in the field of genetic engineering, genetic engineering development services for others, namely, developing transgenic plants and seeds
Additionally, our Cannabis seeds are always fresh and never purchased as bulk material. We only sell quality goods, assessing every seed before shipping. This is why we can guarantee that only seeds with the highest quality are delivered to our customers.
Regular Marijuana seeds means a mixture of male and female seeds. These are avaible with varying proportions. Male plants have to be removed or planted separately in order to avoid pollination. However, if you are planning to breed new seeds, the male plants are essential.
High Supplies Premium Cannabis Seeds are cultivated in the Netherlands. They are hybrids from the breeds Sativa, Indica and Ruderalis. Our Cannabis seed shop is divided into different categories. You can directly search for a breed suited for either indoor or outdoor cultivation or opt for feminized seeds, which, being true to their name, have been modified to grow only female plants. Of course we also offer traditional seeds that develop both male and female plants.
Besides to buying seeds, you can also purchase a complete set of accessories allowing for immediate dissemination.
We offer, among others, the following Cannabis seeds:
The international, multi-disciplinary team of scientists, which includes specialists in ancient genomics, neuro-genetics, population genetics, archaeology, linguistics, and experts in brain health, among others, will focus on creating two unique subsets of genomic data. The first panel is a 5,000 ancient human genomes panel. The second panel will consist of ancient pathogen DNA that is associated with human diseases. Both panels, which will be made publicly available, will together advance our understanding of the evolution of disease variance and its interaction with the human genome and pathogen pressure. The project will generate and analyze one of the largest sets of ancient human and pathogen genome panels ever created.
“Illumina is thrilled to be working with Professor Willerslev and his team on this extraordinary project,” said Paula Dowdy, Senior Vice President and General Manager for Europe, Middle East and Africa at Illumina. “It will be extremely valuable, if by going back 10,000 years, we can acquire new information about when, and under which environmental conditions, a brain disorder may have been introduced into human DNA. This project has the potential to influence future product developments in genetics and precision medicine by providing invaluable insights to those affected by mental health issues.”
“Over the past 10,000 years, mankind has experienced some of the greatest lifestyle changes in the history of our species,” said Professor Willerslev, Lundbeck Foundation Professor at the University of Copenhagen and Prince Philip Professor at the University of Cambridge. “Our diet changed as we developed from hunter-gatherers into farmers, our settlement patterns changed, and there have been changes in pressure of infection from the pathogenic micro-organisms to which we were exposed due to altered living conditions. We also know that chronic viral, bacterial and fungal infections might be causative factors in neuropsychiatric diseases, so there is every reason to believe that the analyses of DNA from this period will show significant trends, giving us the ability to create new, publicly available reference sets, to enhance both the scientific and healthcare communities’ understanding of disease evolution.”
“The NovaSeq 6000 was the obvious choice for this project with its unrivaled data quality and high-throughput capabilities,” remarks Professor Willerslev. “While we conceived this project to explore the evolutionary origins of genetic disorders years ago, it was simply impossible to realize before Illumina’s NovaSeq System came on the market. We are delighted that Lundbeck Foundation had the foresight to see the importance of our project and that Illumina’s technology will make the research possible.”